Abstract
A TRIAL FIBRILLATION is the most prevalent cardiac arrhythmia, occurring in approximately 5% of persons 65 years and older.1 Persons with atrial fibrillation are at an increased risk of having a thromboembolic stroke, with an average yearly risk of 5%.2 This risk is further increased in the presence of risk factors, including congestive heart failure, history of hypertension, history of stroke or transient ischemic attack, and increasing age.2 Long-term antithrombotic therapy with warfarin sodium or aspirin reduces the relative chance of stroke from atrial fibrillation by approximately 65%3,4 and 20%,3,5 respectively. Many studies6-8 have shown that warfarin for prophylaxis of stroke is cost-effective, especially in older persons. Thus, an expert panel recommended that all persons older than 75 years with atrial fibrillation should be considered for long-term warfarin therapy unless a contraindication exists.2

This publication has 59 references indexed in Scilit: